Polyphosphazene immunoadjuvants: Historical perspective and recent advances
Name
nihms-1652407.pdf
Description
Accepted version
Size
2.44 MB
Format
Adobe PDF
Checksum (MD5)
eea87c2f37900fecff520e7719a11965
Author(s)
Andrianov, Alexander K
Langer, Robert
Date Issued
2021
Journal
Journal of Controlled Release
Publisher
Elsevier BV
Citation
Andrianov, Alexander K and Langer, Robert. 2021. "Polyphosphazene immunoadjuvants: Historical perspective and recent advances." Journal of Controlled Release, 329.
Version
Author's final manuscript
Abstract
© 2020 Elsevier B.V. The development of successful vaccines has been increasingly reliant on the use of immunoadjuvants - additives, which can enhance and modulate immune responses to vaccine antigens. Immunoadjuvants of the polyphosphazene family encompass synthetic biodegradable macromolecules, which attain in vivo activity via antigen delivery and immunostimulation mechanisms. Over the last decades, the technology has witnessed evolvement of next generation members, expansion to include various antigens and routes of administration, and progression to clinical phase. This was accompanied by gaining important insights into the mechanism of action and the development of a novel class of virus-mimicking nano-assemblies for antigen delivery. The present review evaluates in vitro and in vivo data generated to date in the context of latest advances in understanding the primary function and biophysical behavior of these macromolecules. It also provides an overview of relevant synthetic and characterization methods, macromolecular biodegradation pathways, and polyphosphazene-based multi-component, nanoparticulate, and microfabricated formulations.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/J.JCONREL.2020.12.001
